Valerion Therapeutics

A $1.2 million MDA grant will help move an experimental cell-penetrating treatment for myotubular myopathy toward human testing

posted on May 30, 2013 - 5:00am
The Muscular Dystrophy Association has awarded $1,195,762 over two years to biotechnology company Valerion Therapeutics (formerly 4s3 Bioscience) for development of a treatment for myotubular myopathy (MTM).

A study seeks people suspected of having myotubular myopathy who have not yet had their MTM1 gene mutation confirmed by a clinically certified lab

posted on April 19, 2013 - 5:00am
Update (May 2, 2013): The names of the collaborators on this study were updated.